Skip to Content

FDA Approves Sensipar

Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients

Sensipar is a first-in-class oral calcimimetic indicated for the treatment of secondary hyperparathyroidism (secondary HPT) in chronic kidney disease (CKD) patients on dialysis, and the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma.

Posted: March 2004

Sensipar (cinacalcet) FDA Approval History